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INTRODUCTION

Pharmaceutical patents are big money these days. This is
good for pharmaceutical companies, because the process of
creating a new drug also costs big money. The process of
research, development, and clinical testing can take years and
may cost a company hundreds of millions of dollars.1 Add in the
cost of drugs that never make it to market, and the cost rises into
the billions.2 In order to see a profit from new pharmaceuticals,
companies seek patent protection.
A patent grants the holder the right to prevent others from
making, using, offering for sale, selling, or importing the
invention in the country where the patent was issued. In order
to better protect patents and other intellectual property, the
World Trade Organization ("WTO") requires that its members
adhere to the Agreement on Trade-Related Aspects of
Intellectual Property Rights ("TRIPS"). The TRIPS Agreement

I J.D., 2013, Chicago-Kent College of Law. My sincere thanks go to Professor
Luis Madrid for planting the seeds that sprouted into this Article, and to Professor
Robert Araujo, S.J., for helping grow them to fruition.

' CONG. BUDGET OFFICE,
PHARMACEUTICAL INDUSTRY 1-2
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(2006), available at http://www.cbo.gov/sites/
default/files/cbofiles/ftpdocs/76xx/doc7615/10-02-drugr-d.pdf.
2 Matthew Herper, The Truly Staggering Cost of Inventing New Drugs, FORBES
(Feb. 10, 2012, 7:41 AM), http://www.forbes.com/sites/matthewherper/2012/02/10/
the-truly-staggering-cost-of-inventing-new-drugs.
I See, e.g., 35 U.S.C.A. § 154(a)(1) (West 2014); 35 U.S.C. § 271(a) (2012); CODE
DE LA PROPRI9Te INTELLECTUELLE [C.P.I.] art. L613-3 (Fr.).
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mandates, among other things, that signatories provide patent
protection for pharmaceuticals, 4 which must last for at least
twenty years.5
It stands to reason that, without these patents, far fewer
useful drugs would be produced because companies would be
unable to recoup the massive investments required to bring a
drug to market.6 At the same time, the lengthy and exclusive
monopoly granted by the patent system can have catastrophic
consequences on the world's "least-developed countries."'
However, TRIPS also allows for compulsory licenses in times of
"national emergency or other circumstances of extreme urgency
or in cases of public non-commercial use."8 The important
question is: Are these provisions working properly, such that
least-developed countries can meet the basic needs of their own
people? Ultimately, are the TRIPS Agreement and its adherents
complying with the dictates of justice and charity?
Enter St. Thomas Aquinas, the great scholastic philosopher.'
Aquinas was a great proponent of the natural law-those
fundamental, universal truths that mankind can comprehend
purely through the use of right reason.1" In his seminal work,
the Summa Theologiae," Aquinas discusses many matters of
I Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.1,
Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization,
Annex IC, 1869 U.N.T.S. 401 [hereinafter TRIPS Agreement], available at
http://www.wto.orglenglish/docs-e/legal-e/27-trips.pdf; TRIPS and Pharmaceutical
Patents, WORLD TRADE ORG. 2 (Sept. 2006), http://www.wto.orgenglish/tratope/
trips-e/tripsfactsheet-pharma_2006_e.pdf.
' TRIPS Agreement art. 33; cf. 35 U.S.C.A. § 154(a)(2); Convention on the Grant
of European Patents art. 63(1), Oct. 5, 1973, 13 I.L.M. 270.
6 This is not necessarily the case, of course. For example, governments could
make the public at large subsidize the costs of developing new drugs through
taxation. However, it is beyond the scope of this Article to comment on the feasibility
or wisdom of such ideas.
I The World Trade Organization acknowledges as "least-developed countries"
those countries designated as such by the United Nations. Cancdn Briefing Notes:
Least-Developed

Countries,

WORLD

TRADE

ORG.

54

(Sept.

9,

2003),

http'//www.wto.org/english/thewto-e/ministe/min03_e/briefe/cancun-presspacke.
pdf.
8 TRIPS Agreement art. 31(b).
' See Daniel Kennedy, St. Thomas Aquinas, in 14 THE CATHOLIC
ENCYCLOPEDIA 663 (1912), available at http://www.newadvent.org/cathen/
14663b.htm.
10 ST. THOMAS AQUINAS, SUMMA THEOLOGIAE, pt. I-II, Q. 94, art. 4 (2d rev. ed.
1920) (1266-1273) [hereinafter SUMMA THEOLOGIAE], available at http'J/www.new
advent.org/summa/2094.htm.
11 Sometimes called the Summa Theologica.
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philosophy and natural law, including notions of justice,
property, and the concept of "the universal destination of goods."
Through proper application of these principles, one can shed light
on the state of the TRIPS Agreement and its conformity-or lack
thereof-with the dictates of objective morality.
Part I of this Article describes the natural law, especially as
it relates to property and the concept of the universal destination
of goods. Part II discusses the history and contents of the TRIPS
Agreement regarding patent law.
Finally, Part III offers
suggestions as to how both rich and poor countries can better
conform to the moral imperatives of the natural law in applying
TRIPS.
I. AQUINAS AND THE NATURAL LAW
The natural law "is nothing else than the rational creature's
participation of the eternal law." 2 It "has its source in the
essence of the just," 3 that "inborn notion of right and wrong" that
resides in human nature. 4
The natural law is therefore
unalterable and applies everywhere and at all times. 5 Moreover,
it is a higher law than the man-made law enacted at any given
time. Indeed, Aquinas says that a law that contradicts reason,
and thus the natural law, is no law at all; it is rather an act of
violence. 6 Ultimately, every law and every legal system ought to
conform to the natural law. 7
A.

Right to PrivateProperty

The natural law fully supports the private ownership of
property. Aquinas says that "man has a natural dominion over
external things, because, by his reason and will, he is able to use

12 SUMMA THEOLOGIAE, supra note 10, pt. I-I,

Q. 91, art. 2; cf. Romans 2:14

(Knox).
13

HEINRICH A. ROMMEN, THE NATURAL LAW 15 (Thomas R. Hanley trans.,

Liberty Fund 1998) (1936).
'"
15

Id. at 34.
Cf.CATECHISM OF THE CATHOLIC CHURCH

1958 (2d ed. 2003), available at

http://www.vatican.va/archive/ENG0015/ _P6U.HTM.
16 SUMMA THEOLOGIAE, supra note 10, pt. I-I, Q. 93, art. 3, quoted in JOHN
XXIII, ENCYCLICAL LETTER PACEM IN TERRIS
51 (1963) [hereinafter PACEM IN
TERRIS]; cf. LEO XIII, ENCYCLICAL LETTER RERUM NOVARUM %[ 52 (1891)
[hereinafter RERUM NOVARUM].
17 Russell Hittinger, Introduction to ROMMEN, supra note 13, at xxvii.
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them for his own profit, as they were made on his account."" By
investing one's time and labor into a thing, a person obtains a
right of ownership over it.' 9 Mankind has understood this
precept even without, and prior to, a government or a body of
property law. Mankind precedes the formation of the State, and
each person has "the right of providing for the substance of his
body" apart from the State.2 ° Ownership is further inherent "in
the norm, 'Thou shalt not steal' ",21 and "the expression[s] 'mine'
and 'thine' [which] occur in every language to indicate
ownership."22 Moreover, ownership of property "is 23founded in
man's natural impulse to extend his own personality.
Furthermore, practical experience confirms the utility of
private property. A person is much more likely to take care, or to
take better care, of what belongs to himself alone, rather than
what belongs to the community at large.24 Private ownership
also creates order; each person has his own particular things to
take care of, "whereas there would be confusion if everyone had
to look after any one thing indeterminately."25 Conversely,
Aquinas observes "that quarrels arise more frequently where
there is no division" of ownership. And a complete abolition of
private property "would rob the lawful possessor, distort the
functions of27 the State, and create utter confusion in the
community."

While the modern patent system did not exist in the days of
Aquinas, 28 arguments in favor of physical property also hold true
for intellectual property. By investing time and labor to create a

18

SUMMA THEOLOGIAE, supra note 10, pt. I-II, Q. 66, art. 1; see Genesis 1:28-30

(Knox).
19 See RERUMNOVARUM, supra note 16,
20
21

Id. 7.
ROMMEN, supra note 13, at 199.

22 Id.

5.

at 206 (quoting 1 HEINRICH VON TREITSCHKE, POLITICS 390 (Blanche

Dugdale & Torben de Bille trans., 1916)).
23 Id. (quoting VON TREITSCHKE, supra note 22, at 391).
24 This is the well-known idea of "the tragedy of the commons." Cf SUMMA
THEOLOGIAE, supra note 10, pt. II-II, Q. 66, art. 2.
25 Id.
26 Id.
4. Here, Pope Leo XIII predicted the
27 RERUM NOVARUM, supra note 16,
effects of the burgeoning Communist movement of his day. See id.
28 However, it seems that patents did exist in some form. For example, in A.D.
1236, a cloth-maker named Bonafusus received a fifteen-year monopoly to weave
cloth in a certain way within the city of Bordeaux. F. D. Prager, The Early Growth
and Influence of IntellectualProperty, 34 J. PAT. OFF. SOC'Y 106, 122 (1952).
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new invention, the inventor exercises dominion over nature in
some form. He thereby gains a kind of ownership, a real
personal interest, over the subject of the invention. Intellectual
property protection incentivizes and helps to spur innovation,
which ultimately adds to the body of public knowledge. The U.S.
Constitution, for example, recognizes that the purpose of the
limited monopoly conferred by a patent is "[tio promote the
Progress of Science and useful Arts."29 An orderly system of
intellectual property also helps to stave off quarrels"° and the
feelings of injustice that result when one person performs all of
the work, only to have another swoop in and copy the invention,
reaping profit without suffering any of the costs. In the modern
economy, "the possession of know-how, technology and skill" is
just as important as land and natural resources, and perhaps
more so. 3 Indeed, "[tihe wealth of the industrialized nations is
based much
more on this kind of ownership than on natural
32
resources."
However, as important as property is, the right to propertywhether physical or intellectual-is not absolute. All rights
necessarily imply corresponding duties, and "the right to own
private property entails a social obligation as well."33 Even
Anglo-American common law recognizes this basic principle in
29

U.S. CONST. art. I, § 8, cl. 8; see also Kewanee Oil Co. v. Bicron Corp., 416

U.S. 470, 480 (1974) (noting that patent laws foster "a positive effect on society
through the introduction of new products and processes of manufacture into the
economy, and the emanations by way of increased employment and better lives for
our citizens").
30 Admittedly, the growth of patent trolls may render this particular argument
less than ironclad.
3' JOHN PAUL II, ENCYCLICAL LETrER CENTESiMUS ANNUS

32 (1991)

[hereinafter CENTESIMUS ANNUS] (emphasis omitted). The Vatican has been a
proponent of the validity and importance of intellectual property for many years.
Archbishop Silvano Tomasi, the Holy See's Permanent Observer to the WTO,

acknowledged that "there is a need to protect intellectual property rights as an
incentive for innovation and technology creation." Archbishop Silvano Tomasi, Head
of Holy See's Observation Delegation, Address at the Plenary Session of the Fourth
Ministerial Conference of the World Trade Organization (Dec. 2005), available at
http://www.zenit.orglen/articles/holy-see-at-world-trade-organization-conference;
see
also Monsignor Franck J. Dewane, Under-Sec'y, Pontifical Council for Justice &
Peace, Statement by the Delegation of the Holy See at the Fifth Ministerial
Conference of the World Trade Organization (Sept. 13, 2003), in WT/MIN(03)/ST/147
(2003) ("[The Holy See wishes to note that the protection of private property,

including intellectual property, is important and must be respected.").
31 CENTESIMUS ANNUS, supra note 31, %32.

' PACEM IN TERRIS, supra note 16,

22.
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multiple ways. For example, the law of nuisance operates on the
maxim "sic utere tuo ut alienum non laedas"-that is, use your
own so as not to injure another's.3 4 The common law also forbids
the use of lethal force merely for the defense of property,
recognizing that life is more valuable than any piece of
property. 5
However, private ownership entails not just negative
obligations, but positive duties as well. According to Aquinas,
"[Mian ought to possess external things, not as his own, but as
common, so that, to wit, he is ready to communicate them to
others in their need."3 6 Here, Aquinas is not condemning private
property, which he soundly defended just a moment ago. Rather,
he is denouncing the rapacious way in which some people treat
their property. Thus, one does not act wrongly if he takes
possession of something that was originally common property,
and then gives others a share, "but he sins if he excludes others
indiscriminately from using it."3 7 Clearly, then, the right to
private property "must be exercised not only for one's own
personal benefit but also for the benefit of others.""
Universal Destinationof Goods

B.

It is self-evident that lesser values must serve, and be
subordinate to, higher values." This notion is recognized by
jurists the world over. For example, the Fifth Amendment to the
U.S. Constitution allows that private property may sometimes be
taken for public use, as long as the government provides "just
compensation."40 Both the Canadian Charter of Rights and
Freedoms and the South African Constitution, among others,
contain a general limitations clause.4 1 Moreover, it is equally
"4See, e.g., Camfield v. United States, 167 U.S. 518, 522-23 (1897).
See, e.g., Katko v. Briney, 183 N.W.2d 657, 659-60 (Iowa 1971) (spring-gun
trap used to defend unoccupied farm house).
36 SUMMA THEOLOGLAE, supra note 10, pt. II-II, Q. 66, art. 2.
37 Id.
35

38

JoHN XXIII, ENCYCLICAL LETTER MATER ET MAGISTRA

19 (1961) (emphasis

added).
" Cf SUMMA THEOLOGIAE, supra note 10, pt. II-II, Q. 66, art. 1 ("[F]or the
imperfect is always for the sake of the perfect...
40 U.S. CONST. amend. V.
41 Canadian Charter of Rights and Freedoms, Part I of the Constitution Act,
1982, being Schedule B to the Canada Act, 1982, c. 1 (U.K.) ("The CanadianCharter
of Rights and Freedoms guarantees the rights and freedoms set out in it subject only
to such reasonable limits prescribed by law as can be demonstrably justified in a free
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self-evident that life is the most basic and fundamental value
upon which the enjoyment of all other rights and values is
based.42 For no one can enjoy property, free speech, or anything
else unless he be allowed to live. Moreover, what person would
deem his continued ownership of mere property as more
important than his very life? Such a decision is manifestly
irrational; the dead cannot use or enjoy property. Therefore, one
can see that the value of life is superior to the value of property.
It follows, then, that one's property must be subordinate in value,
not only to one's own life, but also to the life of another.
As shown above, those who own property must use what is
theirs to help those in need. However, what if a person of means
refuses to acknowledge or act on this duty? The poor man must
not steal from the rich, because theft is immoral." Moreover,
"evil must not be done that good may come" 44 ; put more

colloquially, the ends never justify the means. Because the
natural law is unchanging and universally applicable, its tenets
do not depend on the subjective whims or desires of a particular
person. Moreover, because no one knows the future for certain,
even if one has the best of intentions, the good that he seeks may
never come to fruition. He would thus be left only with evil acts
and bad results. What, then, are the needy to do?
As Aquinas explains, in times of dire need, it is not wrong for
a person to take from another's excess that which one needs to
survive:
[Ilf the need be so manifest and urgent, that it is evident that
the present need must be remedied by whatever means be at
hand (for instance when a person is in some imminent danger,
and there is no other possible remedy), then it is lawful for a
man to succor his own need by means of another's property, by
taking it either openly
or secretly: nor is this properly speaking
45
theft or robbery.

and democratic society."); S. AFR. CONST., 1996, § 36(1) ("The rights in the Bill of
Rights may be limited only ... to the extent that the limitation is reasonable and
justifiable in an open and democratic society based on human dignity, equality and
freedom .... ").
See JOHN PAUL II, POST-SYNODAL APOSTOLIC ExHORTATION CHRISTIFIDELES
38 (1988).
4' SUMMA THEOLOGIAE, supra note 10, pt. II-II, Q. 66, art. 5.
42

LAICI
44
45

Id. pt. II-II, Q. 64, art. 5 (quoting Romans 3:8).
Id. pt. II-II, Q. 66, art. 7.

8
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For example, a starving man may take a bit of food to ward
off starvation. Similarly, a poor man in winter may appropriate
to himself another's coat to keep from freezing to death. And one
who is deathly ill may take the medicine that he needs to heal
himself. Such acts are not stealing-and not immoral-Aquinas
says, "because that which he takes for the support of his life
becomes his own property by reason of that need."4 6 This flows
from what is called "the universal destination of goods":
"[A]ccording to the natural order.., inferior things are ordained
for the purpose of succoring man's needs by their means."4 7 For
example, food exists for the purpose of providing sustenance,
medicine exists to cure the sick, and so on. Moreover, "[t]he
goods of creation are destined for the whole human race."4 They
are ordered towards satisfying the needs of all individuals, not to
remain hidden away by some while others remain in need.
Furthermore, "a man may also take... another's property in
order to succor his neighbor in need." 49 A man does no wrong by
delivering to his neighbor a coat that actually belongs to that
neighbor. Thus, if urgent need makes a coat into the property of
that neighbor, there is likewise no wrong in fetching that coat for
that neighbor-because it is now properly the neighbor's own. Of
course, certain caveats arise. First, it bears repeating that only
"manifest and urgent" need turns another's goods into common
property.5 0 A man's life may trump another's right to property,
but mere comfort or a lack of annoyance do not. Second, the one
in need must only take what another can legitimately spare. A
starving man who takes the last morsel of food from an even
hungrier man clearly wrongs the latter. Thirdly, one ought use
one's own possessions to succor one's neighbor before resorting to
taking from a third person. Only when a person does not have
enough to give to the needy neighbor should he resort to
appropriating the property of another. Finally, even though
taking another's property in time of need is entirely legitimate,
the one who takes must try to restore that property at a later
date-whether by return of the item itself or a replacement

46

Id.

47 Id.
48 CATECHISM OF THE CATHOLIC CHURCH
2402 (2d ed. 2003), available at
httpJ/www.vatican.va/archive/ENG0015/ccc css/archive/catechism/p3s2c2a7.htm.
49 See SUMMA THEOLOGIAE, supra note 10, pt. II-II, Q. 66, art. 7.

50 Id.
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therefor. 51 However, such restoration applies only insofar as is
possible. If the needy man's fortunes never turn around, he will
remain in no position to restore what he took.
Even as the principle of the universal destination of goods
holds true for traditional physical goods, it resonates even
stronger in the realm of intellectual property.
In taking
another's coat, that other person is fully deprived of the use of
the coat. However, the unlicensed production of a patented drug
does not prevent anyone's access to that drug; no pills are being
diverted from shelves in the United States to mouths in Africa.
Finally, although some balk at the very existence of the WTO
and the TRIPS Agreement, international laws on intellectual
property-or indeed any subject-can be good and proper things.
Law "regards first and foremost the order to the common good,"52
and to the extent that laws have the common good as their end,
they are proper things. Indeed, through the use of bilateral and
multilateral agreements, "ties of dependence and feelings of
jealousy-holdovers from the era of colonialism" may "give way to
friendly relationships of true solidarity that are based on
juridical and political equality."5 3 Thus, if properly formed and
administered, agreements like TRIPS can be a source of unity
and prosperity for rich and poor nations alike. But only if
properly formed and administered.
This Article now turns to the TRIPS Agreement, to see how
well it stands upon this moral and philosophical foundation.
Aquinas wrote that "to suitably introduce justice into business
transactions and personal relations is more laborious and
difficult to understand than the remedies in which consists the
whole art of medicine."54 The question is, how well does the

"1 Cf Vincent v. Lake Erie Transp. Co., 124 N.W. 221, 222 (Minn. 1910) (boat
tied to a dock during a sudden storm damaged that dock). In its opinion, the Vincent
court commented, "Theologians hold that a starving man may, without moral guilt,
take what is necessary to sustain life; but it could hardly be said that the obligation
would not be upon such person to pay the value of the property so taken when he
became able to do so." Id.
52 SUMMA THEOLOGIAE, supra note 10, pt. I-II, Q. 90, art. 3.
53 PAUL
VI, ENCYCLICAL LETrER POPULORUM PROGRESSIO
52 (1967)
[hereinafter POPULORUMPROGRESSIO].
"4 St. Thomas Aquinas, Commentary on Aristotle's Nicomachean Ethics, BOOK
V, available at http://oll.libertyfund.org/titles/676 (quoted in ROMMEN, supra note
13, at 223-24).
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TRIPS Agreement handle the weighty task of introducing justice
into business transactions and international relations regarding
medicine?
II.

THE TRIPS AGREEMENT

A.

History
The TRIPS Agreement grew out of the frustrations of many
developed countries at the paucity of protection and enforcement
of intellectual property rights on an international scale.5 5
Discussions came to a head at the Uruguay Round of the General
Agreement on Tariffs and Trade ("GATT") and ultimately paved
the way for both the TRIPS Agreement and the WTO, which
oversees TRIPS.
TRIPS provides for certain minimum
protections for patents and other intellectual property.
Adherents to TRIPS must make patents "available for any
inventions, whether products or processes, in all fields of
technology, provided that they are new, involve an inventive step
and are capable of industrial application."5 6 If a country violates
its obligations under TRIPS, an aggrieved country may subject
the violating country to trade sanctions, subject to WTO
approval.
The stated objective of the TRIPS Agreement is that
[t]he protection and enforcement of intellectual property rights
should contribute to the promotion of technological innovation
and to the transfer and dissemination of technology, to the
mutual advantage of producers and users of technological
knowledge and in a manner conducive to social and economic
58
welfare, and to a balance of rights and obligations.

To that end, TRIPS has several provisions aimed at
advancing the common good-that is, at working toward "the
good of each and, simultaneously, the good of all. 5 9 TRIPS
requires that patents "disclose the invention in a manner
" See Rachel Brewster, The Surprising Benefits to Developing Countries of
Linking InternationalTrade and Intellectual Property, 12 CHI. J. INT'L L. 1, 3 (2011).
6 TRIPS Agreement art. 27(1).
," Understanding the WTO: Settling Disputes, WORLD TRADE ORG.,
http://www.wto.org/english/thewto-e/whatis-eltife/displ-e.htm

(last visited Jan. 8,

2015).
5' TRIPS Agreement art. 7.
'9 Robert John Araujo, S.J., John Courtney Murray, S.J.: The Meaning of Social
Justice in Catholic Thought, 44 LOY. U. CHI. L.J. 331, 334 (2012).
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sufficiently clear and complete for the invention to be carried
out... and may require the applicant to indicate the best mode
for carrying out the invention known to the inventor" at the time
that a patent application is filed.6 0 Such disclosure is a standard
requirement for receiving a patent 6 ' and ensures that the
invention can be practiced by the public after the patent expires.
More importantly, TRIPS also allows for compulsory
licensing-that is, a license to practice the patented invention
without the permission of the patent holder. 62 However, such
licenses come with certain restrictions. A country first must try
to negotiate a license from the patent holder "on reasonable
commercial terms" and over a "reasonable period of time."6 3
However, the country may forego the negotiation requirement "in
the case of a national emergency or other circumstances of
extreme urgency or in cases of public non-commercial use."'
Regardless, the license must be limited in "scope and
duration ...to the purpose for which it was authorized."6 5 The
country must also pay the patent holder "adequate remuneration
in the circumstances of each case. 6 6
Here, one can see the clear influences of the natural law.
The intellectual property right is respected as a general matter,
but with a view of that right's proper limits in favor of the
common good. The patent holder loses a piece of its monopoly
rights when it unreasonably withholds permission, or when
consent can be presumed-as in times of emergency. However,
the licensing country does not get a free ride; its right to practice
the patent is limited to specific circumstances. It also has to offer
"adequate" compensation for the use of the invention.
However, TRIPS initially restricted production of the
patented goods to being "predominantly for the supply of the
domestic market of the Member [country] authorizing such
use."67 This provision rendered the compulsory license of little
benefit to least-developed countries, as these countries so often
lack the means to produce within their own borders the
60
61
62

TRIPS Agreement art. 29(1).
See, e.g., 35 U.S.C. § 112(a) (2012).
See TRIPS Agreement art. 31.
Id. art. 31(b).

64 Id.

" Id. art. 31(c).
art. 31(h).

66 Id.
67

Id. art. 31(f).
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medicines that their people need. 68 Moreover, a third-party
country that attempted to produce the patented drugs and sell
them to its poor neighbors at reduced prices risked trade
sanctions because the drugs thus manufactured would not have
been for "domestic" use.
The resulting concerns over public health came to the fore in
2001 at the WTO's Fourth Ministerial Conference in Doha,
Qatar. The resulting Declaration on the TRIPS Agreement and
Public Health (the "Doha Declaration") specifically recognizes
these issues and sets out a proper interpretation of TRIPS to
address them. Each country "has the right to determine what
constitutes a national emergency" for purposes of the Article 31
compulsory license, as well as "the freedom to determine the
grounds upon which such licences are granted." 69 The Doha
Declaration specifically identifies public health crises involving
AIDS, tuberculosis, and malaria as potential national
emergencies.70 Additionally, least-developed countries need not
offer patent protection for pharmaceuticals until 2016."' By
declining to issue pharmaceutical patents, those least-developed
countries with the means to do so may freely produce the drugs
that they need, with no need to obtain a license from anyone.
The Doha Declaration also acknowledges the plight of those
countries without the means of production.7 2
The WTO
implemented reforms in 2003 that allow wealthier countries to
issue compulsory licenses to supply the needs of countries with
insufficient manufacturing capacity.7 3 However, an exporting
country may produce "only the amount necessary to meet the
needs of the eligible importing Member(s)"; must specifically
label the drugs; and must, insofar as is feasible, "distinguish such
products
through
special
packaging
and/or
special

6 See World Trade Organization, Ministerial Declaration on the TRIPS
Agreement and Public Health,
6, WT/MIN(01)/DEC/2 (2001) [hereinafter Doha
Declaration], available at http://www.wto.org/english/thewto-e/minist-e/min0l_e/
mindecl trips-e.htm.
69

Id. 5(b)-(c).

70

Id. 11.

71

Id. 9%
7.

See id. 916.
General Council Decision, Implementation of Paragraph 6 of the Doha
Declaration on the TRIPS Agreement and Public Health,
2(a), WT/L/540 and
Corr.1 (Sept. 1, 2003), available at http://www.wto.org/englishtratop-e/trips-e/
implem-para6_e.htm.
72
73
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colouring/shaping of the products themselves."7 4 Countries may
also authorize "parallel importation"-that is, when "a product
sold by the patent owner more cheaply in one country is imported
into another without the patent holder's permission." 5 These
changes became a permanent part of the TRIPS Agreement in
December 2005, as Article 31bis and an annex to the
Agreement.7 6
With the implementation of the Doha Declaration, the
TRIPS Agreement seems to align admirably with the natural law
and the universal destination of goods.
While recognizing
intellectual property rights and regarding them as important,
TRIPS prioritizes public health over property and allows nations
with great resources to come to the aid of poor nations in times of
great need. On paper, TRIPS looks very good.77 However, while
such legislation may be necessary, it might not be "sufficient for
setting up true relationships of justice and equity."78 Theory and
practice often diverge, sometimes quite sharply.
B.

Implementation

First the good news.
In February 2005, Canadian
pharmaceutical company Apotex agreed to supply M~decins Sans
Fronti~res 79 with the antiretroviral medicine TriAvir-used to
treat HIV-under Canada's "Paragraph 6 "1° mechanism:
Canada's Access to Medicines Regime ("CAMR"). 1 Ultimately,
Apotex shipped 15.6 million pills to Rwanda-enough to treat
4 Id.

2(b).

TRIPS and Public Health: The Situation in Late 2005, WORLD TRADE ORG.,
http://www.wto.org/english/tratop-e/trips-e/health-background-e.htm (last updated
Nov. 21, 2005).
11 Holger P. Hestermeyer, Canadian-Made Drugs for Rwanda: The First
Application of the WTO Waiver on Patents and Medicines, AM. SOC'v INT'L L.
INSIGHTS (Dec. 10, 2007), http://www.asil.org/insights/volume/11/issue/28/canadianmade-drugs-rwanda-first-application-wto-waiver-patents'and
71
The Holy See's delegation to the WTO even referred to the implementation of
paragraph six of the Doha Declaration as "a positive step in carrying out the Doha
commitments." Dewane, supra note 31.
7'

78

PAUL VI, ENCYCYLICAL

LETTER OCTOGESIMA ADVENIENS

23 (1971)

(emphasis added).
,9 Also known as Doctors without Borders.
80 So named because the issue is addressed in paragraph six of the Doha
Declaration.
81 Canadian
HIV/AIDS Legal Network, History of CAMR Reform,
MEDICINESFORALL.CA, http://www.medicinesforall.ca/history.php (last visited Jan. 8,
2015).
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about 21,000 AIDS victims for a year. 2
However, these
shipments came in September of 2008 and 2009.3 Much of the
several-year delay came from Canada's need to amend its laws
multiple times to properly implement the Paragraph 6 system. 4
Now that the Canadian government has laid the groundwork,
others will hopefully utilize CAMR. Unfortunately, this seems
doubtful. Apotex has stated that it is unlikely to use the law
again in its current form, citing frustrations with the limited
length of the license and the overall complexity of the process.8 5
Moreover, the Canadian government has thus far resisted efforts
to change CAMR, either to cut down on bureaucratic red tape or
to otherwise incentivize manufacturers of generic drugs to
participate.8 6 Even more regrettably, few other countries have
even passed legislation to implement the Paragraph 6 process.
Of those, only two countries-Kenya and South Africa-have
even tried to utilize their legislation, and both times, the drug
manufacturers ran into internal bureaucratic and political
roadblocks.a8

One other reason for Apotex's delay was difficulty in finding
a ready recipient. M6decins Sans Fronti6res could not find a
country willing to import Apotex's TriAvir until Rwanda came
forward in May 2007.11 Other developing and least-developed
countries were hesitant for fear of fall-out from wealthy nations.
Many of these poorer countries rely on donor funding to purchase
important pharmaceuticals, including certain antiretroviral and
anti-malaria medications."
These funds often come with the
condition that the recipients use them to purchase only patented

82
93

Id.
Id.

84 Id.

5 Apotex Inc., Submission to the Standing Committee on Industry, Science and
Technology (Oct. 26, 2010), available at http://www.apotex.com/global/docs/
submissionorderen.pdf.
6 Canadian HIV/AIDS Legal Network, supra note 81.
87 Laura Chung, Use of Paragraph6 System for Access to Medicine, 36 N.C. J.
INT'L L. & COM. REG. 137, 169 (2010).
' Stacey Lee, Access Denied, ONE MAG. (2013), http'//carey.jhu.edu/one/2013/
spring/access-denied.
89 Hestermeyer, supra note 76.
0 Brook K. Baker, Arthritic Flexibilities for Accessing Medicines: Analysis of
WTO Action Regarding Paragraph 6 of the Doha Declaration on the TRIPS
Agreement and Public Health, 14 IND. INT'L & COMP. L. REv. 613, 688 (2004).
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drugs.9 1 Recipient countries are understandably hesitant to risk
losing free money and goodwill for the mere possibility of getting
a better price elsewhere.
Even worse are situations in which pharmaceutical
companies and governments in the developed world retaliate
against countries for issuing compulsory licenses. In 2006, the
government of Thailand issued a compulsory license for the
antiretroviral Efavirenz needed to treat the growing number of
Thai residents infected with HIV.92 The Thai government limited
the license to a five-year term, for the care of no more than
200,000 patients per year, and provided to the patent holder a
royalty of 0.5% of the total sale value-whether imported or
locally produced. 3 The government issued two more compulsory
licenses in 2007, one for the blood-thinner Plavix-used to treat
heart
disease-and
the
other
for
Kaletra-another
antiretroviral-citing the "public health crisis" that constituted a
"national emergency."9 4
Although the compulsory licenses were issued in accordance
with TRIPS, large pharmaceutical companies condemned the
decisions. Bristol-Meyer Squibb stated that the licensing was "a
matter of serious concern."95 Abbott Laboratories went so far as
to keep seven new medicines out of Thailand altogether. 6 The
U.S. government, although admitting that the compulsory
licenses accorded with TRIPS, placed Thailand on its "priority
watch list" as a risk for intellectual property rights violations. 7
Additionally, the major industrialized countries-like the
United States and Canada-have often sought to limit the effects
of the Doha Declaration with multilateral trade agreements that
go beyond what is required by TRIPS-so-called "TRIPS-plus"

"' See Christina Cotter, The Implications of Rwanda's Paragraph6 Agreement
with Canadafor Other Developing Countries, 5 LOY. U. CHI. INT'L L. REV. 177, 178
(2008).
92 Mingchanok Tejavanija, Note, A New Kind of Drug War: Thailand's Taking
on the PharmaceuticalIndustry To Improve Access to HfV/AIDS Drugs Through the
Use of Compulsory Licensing, 28 ARIZ. J. INT'L & COMP. L. 659, 665, 668 (2011).

9' Thai. Dep't of Disease Control, Ministry of Pub. Health, Announcement on the
Public Use of Patent for Pharmaceutical Products, CPTECH.ORG (Nov. 29, 2006),
http://www.cptech.org/ip/health/c/thailand/thaicl4efavirenz.html.
'
Tejavanija, supra note 92, at 673-74.
9' Id. at 671 (internal quotation marks omitted).
Id, at 674.
17 Id. (internal quotation marks omitted).
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agreements.9 8 Among other conditions, these agreements often
require developing and, least-developed countries to limit
compulsory licenses; to limit parallel imports; to protect clinical
data, so that manufacturers of generic drugs would have to
conduct their own lengthy clinical trials before bringing their
drugs to market; and to extend the duration of patents under
certain circumstances, such as delays in patent examinations by
local patent offices.9 9 Typically, these agreements are the result
of severe disparities in bargaining power, such that the poorer
countries "have little ability to negotiate or resist." 10
However, wealthy and powerful countries are not the only
ones trying to abuse the system. Developing and least-developed
countries are not wholly innocent either. Before issuing its
compulsory licenses, Thailand did not, at any time, attempt to
Moreover, it is not
negotiate with the patent holders.''
immediately clear that heart disease amounts to the same kind
of immediate threat posed by diseases like AIDS, such that
Thailand could legitimately declare a state of "national
emergency" for blood thinner. As another example, Brazil has
met with criticism for wielding the possibility of declaring a
national emergency as a weapon, thereby forcing patent holders
to acquiesce to lower pharmaceutical prices rather than risk
India and
compulsory licenses with even worse terms.0 2
Malaysia have threatened to do the same.0 3

'8 Cynthia M. Ho, A New World Orderfor Addressing Patent Rights and Public
Health, 82 CHI.-KENT L. REV. 1469, 1495 (2007).
9 Id. at 1497-98.

100 OXFAM INT'L, OxFAM BRIEFING NOTE: UNDERMINING ACCESS TO MEDICINES:
COMPARISON OF FIVE US FTA'S 2 (2004), available at http://www.twn.my/title2/
FTAsfIntellectual_Property/IP andAccess toMedicines/UnderminingAccessToMed
icines.pdf; cf POPULORUMPROGRESSIO, supra note 53, 5 58 ("It is evident that the
principle of free trade, by itself, is no longer adequate for regulating international
agreements. It certainly can work when both parties are about equal
economically ....But the case is quite different when the nations involved are far
from equal.").
101 Tejavanija, supra note 92, at 684.
102 See, e.g.,
Caroline Manne, Note, Pharmaceutical Patent Protection and
TRIPS: The CountriesThat Cried Wolf and Why Defining "NationalEmergency" Will
Save Them from Themselves, 42 GEO. WASH. INT'L L. REV. 349, 362-63 (2010);
Ubirajara Regis Quintanilha Marques et al., Brazil's AIDS Controversy:
Antiretroviral Drugs, Breaking Patents, and Compulsory Licensing, 60 FOOD &
DRUG L.J. 471, 474 (2005).
103 Tejavanija, supra note 92, at 686.
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III. COMING TOGETHER FOR THE COMMON GOOD

From the foregoing discussion, it is clear that all parties
involved in TRIPS do not always act in conformity with justice or
charity. On all sides, "[t]he pursuit of one's own interest seems to
be the rule for international relations, without the common good
of humanity being taken into consideration.' ' 4
All parties to TRIPS must keep in mind the proper value of
life and property. For their part, developing and least-developed
countries must respect intellectual property rights, including
pharmaceutical patents. Pharmaceutical companies invest great
amounts of time, labor, and money into creating new medicines;
the companies must pay, not only for research materials and lab
equipment, but also the wages of their employees-from the
research chemist to the janitor. To entirely ignore the rights of
patent holders wrongfully deprives those patentees of the income
that would otherwise be theirs as remuneration for the hard
work already expended in bringing the drug to market. Only
about 1 in 50,000 chemical compounds identified will ever make
enough money to meet or exceed the costs invested in research
and development. Of those that make it to market as actual
prescription medications, only about 30% will ever break even or
better. 10 5 Moreover, that return on the investment comes over
the full twenty-year life of the patent.' 6 Without these profits,
new drugs will be fewer in number and frequency. 10 7 Therefore,
beyond moral obligations, countries have practical reasons to pay
what they can for the drugs that they use.
These poorer countries must remember that the universal
destination of goods means that the needy may take what they
need to survive when their need is "manifest and urgent" and
To be sure,
when there is "no other possible remedy."'0 8
impoverished nations like Rwanda cannot afford on-patent prices
and likely have little bargaining power in dealing with
pharmaceutical companies. On the other hand, Brazil is "an

104

CONGREGATION FOR THE DOCTRINE OF THE FAITH, Instruction on Christian

Freedom and Liberation $ 16 (1986).
105 Tejavanija, supra note 92, at 672-73; Manne, supra note 102, at 353.
106 Tejavanija, supra note 92, at 673.
107 Id.
108

See supra Part I.
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upper-middle-income country" under World Bank standards,'0 9
with a gross domestic product of approximately US$2.5 billion."'
Brazil is in a much better position to afford, and to negotiate for,
the medicines that its people need. It therefore has an obligation
to seek other means of acquiring those medicines before resorting
to compulsory licenses, which should be seen as the option of last
resort. Compulsory licenses are certainly legitimate under the
proper circumstances, but no country ought to use them as a
threat to extort lower prices from patent holders. All countries
have a legitimate interest in keeping healthcare costs down, but
pharmaceutical companies must be paid a fair price for the drugs
that they produce. Developing and least-developed countries
must seriously consider how much they can afford to pay. In
some cases, this amount will be zero, or very close to it.
However, in many other cases, it will be substantially higher.
These countries must also be willing to negotiate and accept
just restrictions that are in the interest of their people. In 2005,
the United States offered Brazil over $40 million to help in the
fight against AIDS. 1 ' Brazil, however, turned down the money,
in part because the funds came with requirements that included
denouncing commercial sex work." 2 In the end, this refusal
doubly harms the people of Brazil. First, the people are unable to
benefit from the sizable grant. Second, by continuing to support
risky and immoral sexual behavior, the government puts more
people at risk for HIV infection. Moreover, such actions harm
Brazil's legitimacy when issuing compulsory licenses. One must
wonder whether the government is more concerned with the
welfare of its citizens or its money.
Countries also must ensure that drugs produced under their
compulsory licenses actually make it to the sick. Some of these
drugs may find their way into unscrupulous hands, who will turn
around and sell the drugs on the black market at a substantial
109 Zita Lazzarini, Essay, Making Access to Pharmaceuticalsa Reality: Legal

Options Under TRIPS and the Case of Brazil, 6 YALE HUM. RTS. & DEV. L.J. 103,
130 (2003).
110 World Economic Outlook Database, October 2012: Brazil, INT'L MONETARY
http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/
FUND
(Oct.
2012),
weorept.aspx?sy=2010&ey=2017&scsm=l&ssd= l&sort=country&ds=.&br=l&c=223

&s=NGDPRPCH%2CNGDPD%2CLUR%2CGGXWDGNGDP&grp=O&a=&pr.x=79
&pr.y=4.
"I Marques et al., supra note 102, at 473.
112 Id.
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profit."' Countries have a duty to ensure that pharmaceuticals
are going to the sick people who need them. Additionally, the
patent owners often lose money on sales that they would
otherwise be making in wealthy countries-where people can
better afford the higher prices of on-patent drugs-when
reduced-price drugs make their way across the border.' 14 To help
remedy this problem, TRIPS requires that drugs produced under
compulsory licenses be specifically
labeled
and bear
distinguishing markings, and that these markings be posted to a
particular website before shipment." 5
These measures are
simple ways that countries can help to ensure that medicines
reach their proper destination, but more vigilance may be
required. Ultimately, when least-developed countries receive
low-priced drugs, they have a duty to ensure that the drugs reach
those people within their own borders who have dire need, rather
than ending up in the hands of mere profiteers.
However, patent owners and wealthy nations are not
blameless either. They must remember that the purpose of
medicine is to heal the sick, not to make a profit. Profit is good
and necessary to a business, to be sure, and there is nothing
innately wrong with making money. However, "profitability is
not the only indicator of a firm's condition .... [O]ther human
and moral factors must also be considered." 6 Companies must
not permit "economics to be separated from human realities,"
7
especially the reality of the suffering poor."
Pharmaceutical companies also must remember that the
purpose of patents is to benefit "social and economic welfare." 118
The duties of property ownership require that patent holders
treat their inventions "not as [their] own, but as common,"
always "ready to communicate them to others in their need."' 9
To be sure, pharmaceutical companies sometimes do just that.
,' Richard A. Epstein & F. Scott Kieff, Questioning the Frequency and Wisdom
of Compulsory Licensing for PharmaceuticalPatents, 78 U. CHI. L. REV. 71, 81-82
(2011).
114 See id. at 81.

11
World Trade Organization General Council, Amendment of the TRIPS
Agreement, Annex, T 2(b)(ii)-(iii), WT/L/641 (Dec. 6, 2005).
116 CENTESIMUSANNUS, supra note 31,
35 (emphasis omitted).
117 POPULORUM PROGRESSIO, supra note 53,
14 (citing L. J. Lebret, O.P.,
Dynamique concrte du ddveloppement Paris: Economie et Humanisme, Les editions
ouvrier~s (1961), 28).
118 TRIPS Agreement art. 7.
119 SUMMA THEOLOGIAE, supra note 10, pt. I-II, Q. 66, art. 2.
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For example, in 2012, several companies teamed up and pledged
to give away over 14 billion doses of medication to treat
"neglected tropical diseases" like sleeping sickness and leprosy. 2 '
Certainly, these efforts are to be lauded.
Nevertheless, unless and until the existence of a
pharmaceutical company is endangered, neither that company
nor its home government may morally prevent those in need from
receiving life-saving medicines, no matter what the disease.' 2 '
No amount of profit can ever outweigh the inestimable value of a
human life, and the mere quest for profit can never take
precedence over a human life. Furthermore, it is questionable
that large pharmaceutical companies are especially harmed by
compulsory licenses and parallel imports. At least as of 2007, the
United States, Canada, Europe, and Japan collectively made up
nearly 89% of global pharmaceutical sales by dollar volume,
while all of Africa and Asia-minus Japan-amounted to a mere
5. 1%. 1
In many cases, compulsory licenses do not cost
pharmaceutical companies anything at all because the countries
issuing the licenses would not otherwise be purchasing the drugs
in question. 23
Even if they are harmed, pharmaceutical companies will
likely survive the blow. For example, in 2013, Pfizer reported a
net income of over $22 billion-a 51% increase over 2012.124

During the same period, Novartis reported over $9.2 billion in
120 Kate Kelland, Big Pharma Donates Drugs for Neglected Diseases, REUTERS
(Jan. 30, 2012, 6:00 AM), http://www.reuters.com/article/2012/01/30/diseasesneglected-pharma-idUSL5E8CU17B20120130.
121 As for the proper course of action when a pharmaceutical manufacturer is
threatened with bankruptcy due to unlicensed drug production, this author notes
only that the matter is one on which reasonable people may disagree. However, this
author is inclined to think that the company could justifiably defend its own
existence, both for the sake of its employees-to prevent unemployment,
homelessness, and the like-and to help ensure the research and development of
new medicines. Again, however, these justifications only go so far.
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23,
2007),
2324.php.
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Many people

use a

similar argument

to spuriously justify copyright

infringement for things like illegal music downloads. One key difference lies in the
nature of the goods in question. Medicine is necessary to preserve the life of a sick
person. One strains to conceive of a scenario in which someone could make a similar
claim for a song or movie.
124 PFIZER, PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;
PROVIDES 2014 FINANCIAL GUIDANCE (2014), available at http://www.pfizer.com/
system/files/presentation/Q4_2013_EarningsjhasfdJLKFdsfljkDFSIM.pdf.
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net profits-admittedly, a very minor 1% drop from 2012.125
Bayer Group reported gross profits 126 of over C20.8 billion-or
$28.6 billion-across itself and all of its subsidiaries in 2013,127
which is slightly up from almost E20.7 billion in profits in 2012.128
Clearly, big pharmaceutical companies are not presently in
danger of being driven out of business, even by robust
compulsory licenses and parallel imports.
Finally, countries in the developed world have obligations, as
well. These countries would do well to remember that the poor
are not a burden, that they are not "irksome intruders trying to
consume what others have produced."1 29 Rather, the poor are
fellow human beings, possessed of the same inviolable dignity as
the wealthiest person in the developed world. Wealthy countries
ought to encourage the use of parallel imports and should amend
their laws so that the process both exists and allows for a
streamlined, efficient process so that the medicines produced will
reach their destinations as quickly as possible.
Moreover,
obviously, neither governments nor pharmaceutical companies
should attempt to punish countries for obtaining necessary
compulsory licenses or parallel imports.
Rather, developed
countries would do well to heed the warning of Pope Paul VI: "If
prosperous nations continue to be jealous of their own advantage
alone, they will jeopardize their highest values, sacrificing the
pursuit of excellence to the acquisition of possessions."'
CONCLUSION
As Aquinas says, "[Whatever certain people have in
superabundance is due, by natural law, to the purpose of
succoring the poor."' 3 ' Ultimately, more frequent and expanded
use of the TRIPS compulsory license is to be encouraged, so long
12 Pharma Giant Novartis Reports Profits Dip, NEWS.COM.AU (Jan. 29, 2014,
8:47 PM), https://web.archive.org/web/20140131111831/http J/www.news.com.au/
finance/business/novartis-q4-net-profit-rises-to-us2b/story-e6frfkur- 1226813289371.
126 Of course, net profits is a better indicator of corporate health, but that figure
was not available in the financial data at the time of this writing. Apologizes to the
fiscally-minded reader. See generally BAYER, ANNUAL REPORT 2013 (2014),
available
at
httpJ/www.annualreport20l3.bayer.com/en/bayer-annual-reportaugmented-version-2013.pdfx.
127 Id. at 176.
128 Id.
129 CENTESIMUSANNUS, supra note 31,
28.
130 POPULORUMPROGRESSIO,supra note 53,
49.
131 SUMMA THEOLOGIAE, supra note 10, pt. Il-II, Q. 66, art. 7.
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as these licenses are issued justly. Neither pharmaceutical
companies nor wealthy governments ought to prevent the poor
and needy from accessing what is theirs by natural right.

